Auxilium Pharmaceuticals Inc. (AUXL) announced positive results from a phase IIa study on Xiaflex (collagenase clostridium histolyticum or CCH), being evaluated for the treatment of dematous fibrosclerotic panniculopathy (EFP), which is commonly known as cellulite. The company’s shares jumped 4.39% on the news.
According to the data presented by the Auxilium Pharma, all three doses (low (0.06mg), mid (0.48mg) and high (0.84mg)) evaluated in the randomized, double-blind study showed an improvement in the appearance of the cellulite. The company said that a statistically significant improvement in the appearance of the cellulite was observed in the mid and high dosage groups compared to placebo.
In the study, 68% of the both the mid and high dose patients were reported to be satisfied or very satisfied compared to the placebo arm patients (34%). The candidate was also found to be well-tolerated.
On the back of encouraging data, Auxilium Pharma intends to initiate a phase IIb clinical trial in the second quarter of 2015.
Xiaflex is currently approved for Dupuytren's contracture and Peyronie’s. We are encouraged by Auxilium Pharma's efforts to expand Xiaflex’s label. Xiaflex generated sales of $26.3 million in the U.S in the second quarter of 2014, up 75.3% from the year-ago period. Approval for additional indications will boost sales of the drug. Xiaflex is currently in phase II development for frozen shoulder syndrome besides cellulite. Meanwhile, the FDA will be deciding on Xiaflex’s label expansion for the treatment of two Dupuytren's contracture cords concurrently in October.
Auxilium Pharma is a Zacks Rank #4 (Sell) stock. Some better-ranked stocks in the healthcare sector include Endo International plc (ENDP), Hyperion Therapeutics, Inc. (HPTX) and United Therapeutics Corp. (UTHR). All three carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment